Corrigendum: Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study [Front Immunol, 8, (2017), (386)] doi: 10.3389/fimmu.2017.00386
Articolo
Data di Pubblicazione:
2018
Abstract:
A corrigendum on Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study by Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, et al. Front Immunol (2017) 8:386. doi: 10.3389/fimmu.2017.00386. In the original article, affiliation number 9 was wrong. The correct affiliation 9 is "Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy". This error does not change the scientific conclusions of the article in any way. The original article has been updated. Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Tipologia CRIS:
03A-Articolo su Rivista
Keywords:
Best overall response; CTLA-4 variants; Ipilimumab; Melanoma; Overall survival; Predictive/prognostic factor
Elenco autori:
Queirolo P.; Dozin B.; Morabito A.; Banelli B.; Piccioli P.; Fava C.; Leo C.; Carosio R.; Laurent S.; Fontana V.; Ferrucci P.F.; Martinoli C.; Cocorocchio E.; Battaglia A.; Ascierto P.A.; Capone M.; Simeone E.; De Galitiis F.; Pagani E.; Cappellini G.C.A.; Marchetti P.; Guida M.; Tommasi S.; Mandala M.; Merelli B.; Quaglino P.; Fava P.; Guidoboni M.; Romani M.; Spagnolo F.; Pistillo M.P.
Link alla scheda completa:
Pubblicato in: